Citius Pharmac Dl Stock Net Income
| 47N Stock | EUR 3.29 0.00 0.00% |
CITIUS PHARMAC DL fundamentals help investors to digest information that contributes to CITIUS PHARMAC's financial success or failures. It also enables traders to predict the movement of CITIUS Stock. The fundamental analysis module provides a way to measure CITIUS PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CITIUS PHARMAC stock.
CITIUS |
CITIUS PHARMAC DL Company Net Income Analysis
CITIUS PHARMAC's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current CITIUS PHARMAC Net Income | (23.66 M) |
Most of CITIUS PHARMAC's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CITIUS PHARMAC DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CITIUS PHARMAC DL reported net income of (23.66 Million). This is 106.93% lower than that of the Healthcare sector and 133.78% lower than that of the Biotechnology industry. The net income for all Germany stocks is 104.14% higher than that of the company.
CITIUS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CITIUS PHARMAC's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CITIUS PHARMAC could also be used in its relative valuation, which is a method of valuing CITIUS PHARMAC by comparing valuation metrics of similar companies.CITIUS PHARMAC is currently under evaluation in net income category among its peers.
CITIUS Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Shares Outstanding | 146.21 M | |||
| Shares Owned By Insiders | 8.42 % | |||
| Shares Owned By Institutions | 11.00 % | |||
| EBITDA | (33.31 M) | |||
| Net Income | (23.66 M) | |||
| Cash And Equivalents | 115.66 M | |||
| Cash Per Share | 0.79 X | |||
| Total Debt | 1.06 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 32.48 X | |||
| Book Value Per Share | 0.70 X | |||
| Cash Flow From Operations | (22.02 M) | |||
| Earnings Per Share | (0.19) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 21 | |||
| Beta | 1.2 | |||
| Market Capitalization | 186.2 M |
About CITIUS PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CITIUS PHARMAC DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CITIUS PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CITIUS PHARMAC DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.